WHAT THIS STUDY SHOWS
Key Findings from the Clinical Study
This clinical study evaluates omega 3 bonded to phospholipids using Naturmega’s Ruby-O® BPL-O3™ technology. The findings demonstrate improved triglyceride target attainment and enhanced Omega 3 Index support at a lower dose compared to standard triglyceride forms.
• Improved triglyceride target attainment
• Enhanced Omega 3 Index support
• Lower dose compared to standard triglyceride omega 3
• Efficient delivery through BPL-O3™ technology
THE TECHNOLOGY
What is Ruby-O® BPL-O3™ Technology?
Ruby-O® BPL-O3™ (Bonded Phospholipid Omega 3) technology structures omega 3 in a form designed to enhance cellular delivery and utilization. By bonding omega 3 to phospholipids, the formulation supports more efficient biological integration compared to conventional triglyceride forms.
COMMERCIAL RELEVANCE
Implications for Brands
For brands seeking meaningful differentiation in the omega 3 category, this study provides scientific validation for a lower-dose, performance-oriented approach.
Ruby-O® Balance is commercially available as a ready-to-market formulation powered by BPL-O3™ technology, enabling:
• Premium positioning
• Science-backed claims
• Dose efficiency
• Faster commercial implementation
Download the Full Study
<sup><i>Ruby-O® is a registered trademark of Naturmega and may be featured as a branded ingredient on product labels and marketing materials, subject to agreement.</i></sup>
